Finally, duration of follow-up was only 12–16 weeks; a longer follow-up period would be useful to identify long-term effects of GLP-1 receptor agonists on mental health and effects of newer, perhaps more efficacious GLP-1 receptor agonists at higher doses which have since been approved e.g. subcutaneous semaglutide (up to a dose of 2.4 mg weekly), or dual gastric inhibitory polypeptide (GIP)/GLP-1 receptor agonists e.g. tirzepatide, approved for T2D and undergoing appraisal currently by the National Institute for Health and Care Excellence (NICE) for obesity. Here, GLP1R is linked to obesity disorder.